Sertraline Hydrochloride

Sertraline Hydrochloride

Sertraline Hydrochloride Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.

There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1.

Table 1
Age Range
Drug-Placebo Difference in
Number of Cases of Suicidality per
1000 Patients Treated
 
Increases Compared to Placebo
<18
14 additional cases
18 to 24
5 additional cases
 
Decreases Compared to Placebo
25 to 64
1 fewer case
>65
6 fewer cases

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.


The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. 

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. 

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION—Discontinuation of Treatment with Sertraline Hydrochloride Tablets, for a description of the risks of discontinuation of sertraline hydrochloride).

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers.
Such monitoring should include daily observation by families and caregivers. Prescriptions for sertraline hydrochloride should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.

 

A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that sertraline hydrochloride is not approved for use in treating bipolar depression.


 

The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including sertraline hydrochloride, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of sertraline hydrochloride with MAOIs intended to treat psychiatric disorders is contraindicated. Sertraline hydrochloride should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking sertraline hydrochloride. Sertraline hydrochloride should be discontinued before initiating treatment with the MAOI (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).

If concomitant use of sertraline hydrochloride with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John’s Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.

Treatment with sertraline hydrochloride and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.

Angle-Closure Glaucoma

The pupillary dilation that occurs following use of many antidepressant drugs including sertraline hydrochloride may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.

 

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Major Depressive Disorder

Sertraline hydrochloride tablets USP are indicated for the treatment of major depressive disorder in adults.

The efficacy of sertraline hydrochloride tablets USP in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY).

A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. 

The antidepressant action of sertraline hydrochloride tablets USP in hospitalized depressed patients has not been adequately studied.

The efficacy of sertraline hydrochloride tablets USP in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets USP for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY).

Obsessive-Compulsive Disorder

Sertraline hydrochloride tablets USP are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning.

The efficacy of sertraline hydrochloride tablets USP were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY).

Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. 

The efficacy of sertraline hydrochloride tablets USP in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets USP and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use sertraline hydrochloride tablets USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).

Panic Disorder

Sertraline hydrochloride tablets USP are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. 

The efficacy of sertraline hydrochloride tablets USP were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY).

Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes.

The efficacy of sertraline hydrochloride tablets USP in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets USP and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use sertraline hydrochloride tablets USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).

Posttraumatic Stress Disorder (PTSD)

Sertraline hydrochloride tablets USP are indicated for the treatment of posttraumatic stress disorder in adults.

The efficacy of sertraline hydrochloride tablets USP in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY).

PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

The efficacy of sertraline hydrochloride tablets USP in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).

Premenstrual Dysphoric Disorder (PMDD)

Sertraline hydrochloride tablets USP are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. 

The efficacy of sertraline hydrochloride tablets USP in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III­-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY). 

The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control.  Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant.

The effectiveness of sertraline hydrochloride tablets USP in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials.  Therefore, the physician who elects to use sertraline hydrochloride tablets USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). 

Social Anxiety Disorder

Sertraline hydrochloride tablets USP are indicated for the treatment of social anxiety disorder, also known as social phobia in adults.

The efficacy of sertraline hydrochloride tablets USP in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY). 

Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. 

The efficacy of sertraline hydrochloride tablets USP in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets USP treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets USP for extended periods should periodically re-­evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY).

 

History

There is currently no drug history available for this drug.

Other Information

Sertraline hydrochloride tablets USP are a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride. The molecular formula C17H17NCl2•HCl is represented by the following structural formula:

MM1

Sertraline hydrochloride USP is a white crystalline powder that is slightly soluble in water and isopropyl alcohol, and sparingly soluble in ethanol.

Sertraline hydrochloride tablets USP are supplied for oral administration as scored tablets containing sertraline hydrochloride USP equivalent to 25 mg, 50 mg, and 100 mg of sertraline and the following inactive ingredients: microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, dibasic calcium phosphate dihydrate, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, and polysorbate 80. Besides, 25 mg contains D&C yellow #10 aluminum lake, FD&C blue #1 aluminum lake, FD&C red #40 aluminum lake; 50 mg contains FD&C blue #2 aluminum lake; and 100 mg contains iron oxide yellow.

Meets USP dissolution test 2.

 

Sertraline Hydrochloride Manufacturers


  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Accord Healthcare, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Accord Healthcare, Inc.]
  • Cobalt Pharmaceuticals
    Sertraline Hydrochloride (Sertraline Hydrochloride) Tablet, Film Coated [Cobalt Pharmaceuticals]
  • Zydus Pharmaceuticals Usa Inc.
    Sertraline Hydrochloride (Sertraline Hydrochloride) Tablet, Film Coated [Zydus Pharmaceuticals Usa Inc.]
  • Watson Laboratories, Inc.
    Sertraline Hydrochloride (Sertraline Hydrochloride) Tablet [Watson Laboratories, Inc.]
  • Actavis Elizabeth Llc
    Sertraline Hydrochloride Tablet [Actavis Elizabeth Llc]
  • Hikma Pharmaceutical
    Sertraline Hydrochloride Tablet, Film Coated [Hikma Pharmaceutical]
  • Contract Pharmacy Services-pa
    Sertraline Hydrochloride Tablet, Film Coated [Contract Pharmacy Services-pa]
  • State Of Florida Doh Central Pharmacy
    Sertraline Hydrochloride Tablet, Film Coated [State Of Florida Doh Central Pharmacy]
  • State Of Florida Doh Central Pharmacy
    Sertraline Hydrochloride Tablet, Film Coated [State Of Florida Doh Central Pharmacy]
  • State Of Florida Doh Central Pharmacy
    Sertraline Hydrochloride Tablet, Film Coated [State Of Florida Doh Central Pharmacy]
  • Pd-rx Pharmaceuticals, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • Pd-rx Pharmaceuticals, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • Mckesson Packaging Services Business Unit Of Mckesson Corporation
    Sertraline Hydrochloride Tablet, Film Coated [Mckesson Packaging Services Business Unit Of Mckesson Corporation]
  • Rebel Distributors Corp
    Sertraline Hydrochloride Tablet, Film Coated [Rebel Distributors Corp]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Cardinal Health
    Sertraline Hydrochloride Tablet [Cardinal Health]
  • Bryant Ranch Prepack
    Sertraline Hydrochloride Tablet [Bryant Ranch Prepack]
  • Aurolife Pharma Llc
    Sertraline Hydrochloride Tablet [Aurolife Pharma Llc]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet [Remedyrepack Inc. ]
  • Keltman Pharmaceuticals Inc.
    Sertraline Hydrochloride Tablet [Keltman Pharmaceuticals Inc.]
  • Pd-rx Pharmaceuticals, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • West-ward Pharmaceutical Corp
    Sertraline Hydrochloride Tablet, Film Coated [West-ward Pharmaceutical Corp]
  • Stat Rx Usa Llc
    Sertraline Hydrochloride Tablet [Stat Rx Usa Llc]
  • Medvantx, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Medvantx, Inc.]
  • Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
    Sertraline Hydrochloride Tablet, Film Coated [Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc]
  • H.j. Harkins Company Inc.
    Sertraline Hydrochloride Tablet [H.j. Harkins Company Inc.]
  • Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
    Sertraline Hydrochloride Tablet, Film Coated [Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc]
  • Kaiser Foundation Hospitals
    Sertraline Hydrochloride Tablet, Film Coated [Kaiser Foundation Hospitals]
  • Life Line Home Care Services
    Sertraline Hydrochloride Tablet, Film Coated [Life Line Home Care Services]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet [Remedyrepack Inc. ]
  • Unit Dose Services
    Sertraline Hydrochloride Tablet [Unit Dose Services]
  • Unit Dose Services
    Sertraline Hydrochloride Tablet [Unit Dose Services]
  • Unit Dose Services
    Sertraline Hydrochloride Tablet [Unit Dose Services]
  • Mckesson Contract Packaging
    Sertraline Hydrochloride Tablet [Mckesson Contract Packaging]
  • Aphena Pharma Solutions – Tennessee, Inc.
    Sertraline Hydrochloride (Sertraline) Tablet, Film Coated [Aphena Pharma Solutions – Tennessee, Inc.]
  • Mylan Institutional Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Mylan Institutional Inc.]
  • Bryant Ranch Prepack
    Sertraline Hydrochloride Tablet [Bryant Ranch Prepack]
  • Bryant Ranch Prepack
    Sertraline Hydrochloride Tablet, Film Coated [Bryant Ranch Prepack]
  • Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
    Sertraline Hydrochloride Tablet [Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc]
  • Pd-rx Pharmaceuticals, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • Pd-rx Pharmaceuticals, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • Greenstone Llc
    Sertraline Hydrochloride Tablet, Film Coated Sertraline Hydrochloride Solution, Concentrate [Greenstone Llc]
  • Ranbaxy Pharmaceuticals Inc.
    Sertraline Hydrochloride Tablet, Coated [Ranbaxy Pharmaceuticals Inc.]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Mylan Pharmaceuticals Inc.
    Sertraline Hydrochloride (Sertraline) Tablet, Film Coated [Mylan Pharmaceuticals Inc.]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet [Remedyrepack Inc. ]
  • Camber Pharmaceuticals Inc.
    Sertraline Hydrochloride Tablet [Camber Pharmaceuticals Inc.]
  • Aurobindo Pharma Limited
    Sertraline Hydrochloride Tablet, Film Coated [Aurobindo Pharma Limited]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Preferred Pharmaceuticals, Inc
    Sertraline Hydrochloride Tablet [Preferred Pharmaceuticals, Inc]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Sertraline Hydrochloride ( Sertraline Hydrochloride ) Tablet, Film Coated [Remedyrepack Inc. ]
  • Med-health Pharma, Llc
    Sertraline Hydrochloride Tablet, Film Coated [Med-health Pharma, Llc]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Major Pharmaceuticals
    Sertraline Hydrochloride Tablet [Major Pharmaceuticals]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet [Remedyrepack Inc. ]
  • Torrent Pharmaceuticals Limited
    Sertraline Hydrochloride Tablet, Film Coated [Torrent Pharmaceuticals Limited]
  • International Labs, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [International Labs, Inc.]
  • Medvantx, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Medvantx, Inc.]
  • Medvantx, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Medvantx, Inc.]
  • Apotex Corp
    Sertraline Hydrochloride Tablet, Film Coated [Apotex Corp]
  • Clinical Solutions Wholesale
    Sertraline Hydrochloride Tablet [Clinical Solutions Wholesale]
  • St Marys Medical Park Pharmacy
    Sertraline Hydrochloride Tablet [St Marys Medical Park Pharmacy]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Physicians Total Care, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Physicians Total Care, Inc.]
  • American Health Packaging
    Sertraline Hydrochloride Tablet [American Health Packaging]
  • Aidarex Pharmaceuticals Llc
    Sertraline Hydrochloride Tablet [Aidarex Pharmaceuticals Llc]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Sertraline Hydrochloride Tablet, Film Coated [Remedyrepack Inc. ]
  • Mylan Institutional Inc.
    Sertraline Hydrochloride (Sertraline) Tablet, Film Coated [Mylan Institutional Inc.]
  • Cardinal Health
    Sertraline Hydrochloride Tablet, Film Coated [Cardinal Health]
  • Legacy Pharmaceutical Packaging
    Sertraline Hydrochloride Tablet [Legacy Pharmaceutical Packaging]
  • Lake Erie Medical Dba Quality Care Products Llc
    Sertraline Hydrochloride Tablet [Lake Erie Medical Dba Quality Care Products Llc]
  • International Labs, Inc.
    Sertraline Hydrochloride Tablet, Film Coated [International Labs, Inc.]
  • Cardinal Health
    Sertraline Hydrochloride Tablet [Cardinal Health]
  • Legacy Pharmaceutical Packaging
    Sertraline Hydrochloride Tablet [Legacy Pharmaceutical Packaging]
  • Cipla Limited
    Sertraline Hydrochloride Tablet [Cipla Limited]
  • Northstar Rx Llc
    Sertraline Hydrochloride Tablet, Film Coated [Northstar Rx Llc]
  • Tya Pharmaceuticals
    Sertraline Hydrochloride Tablet [Tya Pharmaceuticals]
  • State Of Florida Doh Central Pharmacy
    Sertraline Hydrochloride (Sertraline) Tablet, Film Coated [State Of Florida Doh Central Pharmacy]
  • Cardinal Health
    Sertraline Hydrochloride Tablet, Film Coated [Cardinal Health]
  • Legacy Pharmaceutical Packaging, Llc
    Sertraline Hydrochloride Tablet [Legacy Pharmaceutical Packaging, Llc]
  • Legacy Pharmaceutical Packaging, Llc
    Sertraline Hydrochloride Tablet [Legacy Pharmaceutical Packaging, Llc]